scholarly journals Nanoparticle Delivery of Antisense Oligonucleotides and Their Application in the Exon Skipping Strategy for Duchenne Muscular Dystrophy

2014 ◽  
Vol 24 (1) ◽  
pp. 87-100 ◽  
Author(s):  
Maria Sofia Falzarano ◽  
Chiara Passarelli ◽  
Alessandra Ferlini
2009 ◽  
Vol 11 (3) ◽  
pp. 257-266 ◽  
Author(s):  
Hans A. Heemskerk ◽  
Christa L. de Winter ◽  
Sjef J. de Kimpe ◽  
Petra van Kuik-Romeijn ◽  
Niki Heuvelmans ◽  
...  

Molecules ◽  
2012 ◽  
Vol 17 (2) ◽  
pp. 1138-1148 ◽  
Author(s):  
Linda J. Popplewell ◽  
Aseel Abu-Dayya ◽  
Tushar Khanna ◽  
Marcella Flinterman ◽  
Nada Abdul Khalique ◽  
...  

2018 ◽  
Vol 26 (1) ◽  
pp. 132-147 ◽  
Author(s):  
Silvana M.G. Jirka ◽  
Peter A.C. ’t Hoen ◽  
Valeriano Diaz Parillas ◽  
Christa L. Tanganyika-de Winter ◽  
Ruurd C. Verheul ◽  
...  

2019 ◽  
Vol 29 (6) ◽  
pp. 305-322 ◽  
Author(s):  
Sieto Bosgra ◽  
Jessica Sipkens ◽  
Sjef de Kimpe ◽  
Cathaline den Besten ◽  
Nicole Datson ◽  
...  

Author(s):  
Yoshitsugu Aoki ◽  
◽  
Tetsuya Nagata ◽  
Shin’ichi Takeda

Duchenne Muscular Dystrophy (DMD) is a lethalmuscle disorder characterized by mutations in the DMD gene. These mutations primarily disrupt the reading frame, resulting in the absence of functional dystrophin protein. Exon skipping, which involves the use of antisense oligonucleotides is a promising therapeutic approach for DMD, and clinical trials on exon skipping are currently underway in DMD patients. Recently, stable and less-toxic antisense oligonucleotides with higher efficacy have been developed in mouse and dog models of DMD. This review highlights a new approach for antisense oligonucleotide-based therapeutics for DMD, particularly for exon skipping-based methods.


Sign in / Sign up

Export Citation Format

Share Document